Alembic Pharmaceuticals receives USFDA Tentative Approval for Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg

Alembic Pharmaceuticals Limited today announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban Tablets are indicated for i) the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ii) the treatment of deep vein thrombosis (DVT). iii) the treatment of pulmonary embolism (PE). iv) the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE. and v) the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.

Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg have an estimated market size of US$ 6.1 billion for twelve months ending March 2020 according to IQVIA.

Alembic now has a total of 124 ANDA approvals (110 final approvals and 14 tentative approvals) from USFDA.

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.945.95 as compared to the previous close of Rs. 908.3. The total number of shares traded during the day was 49099 in over 4650 trades.

The stock hit an intraday high of Rs. 950 and intraday low of 899. The net turnover during the day was Rs. 45794507.

Source : Equity Bulls

Keywords